Y. Emre Gencay and colleagues have developed engineered phages with CRISPR-Cas machinery to reduce E. coli in mice. The phages, called SNIPR001, were well tolerated in mouse models and minipigs, and out-competed their ancestral wild-type phages in coculture experiments. SNIPR001 is in clinical development and may benefit hematological cancer patients.